Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.220
-0.040 (-0.94%)
At close: Feb 21, 2025, 4:00 PM
4.320
+0.100 (2.37%)
After-hours: Feb 21, 2025, 4:41 PM EST
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $24.63M in the quarter ending September 30, 2024, with 433.79% growth. This brings the company's revenue in the last twelve months to $163.78M, up 3.40% year-over-year. In the year 2023, Voyager Therapeutics had annual revenue of $250.01M with 511.16% growth.
Revenue (ttm)
$163.78M
Revenue Growth
+3.40%
P/S Ratio
1.43
Revenue / Employee
$1,011,012
Employees
162
Market Cap
230.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
Dec 31, 2019 | 104.39M | 96.77M | 1,270.14% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VYGR News
- 2 hours ago - The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 14 hours ago - VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 1 day ago - The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 11 days ago - Voyager Provides Update on SOD1 ALS Gene Therapy Program - GlobeNewsWire
- 22 days ago - Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance - Seeking Alpha
- 3 months ago - Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Voyager Reports Third Quarter 2024 Financial and Operating Results - GlobeNewsWire
- 3 months ago - Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewsWire